| Size | Price | |
|---|---|---|
| 100mg | ||
| 250mg | ||
| 500mg | ||
| Other Sizes |
| References |
1: Anand IS, Hughes LO, Whittington JR, Raftery EB. Acute haemodynamic effects of different doses of alifedrine in congestive heart failure. Eur J Clin Pharmacol. 1989;36(4):335-41. PubMed PMID: 2737225. 2: Wan SK, Hoff W, Evans TR. Haemodynamic effects of intravenous and oral alifedrine in patients with cardiac failure. Curr Med Res Opin. 1988;11(4):242-53. PubMed PMID: 3215041. 3: Schanzenbächer P, Riegger G, Liebau G, Hockerts T, Kochsiek K. [Acute hemodynamic effects of alifedrine in patients with heart failure]. Z Kardiol. 1984 Feb;73(2):95-100. German. PubMed PMID: 6719988. 4: Wainwright CL, Parratt JR. Alifedrine, a positive inotropic agent that moderately reduces the severity of ischaemia and reperfusion-induced ventricular arrhythmias. Eur J Pharmacol. 1988 Mar 15;147(3):373-80. PubMed PMID: 3378563. 5: Metzenauer P, Dedecke R, Göbel H, Martorana PA, Stroman F, Szelenyi I. Effects of the novel beta-adrenergic partial agonist alifedrine on cardiac performance in dogs with acute ischemic left ventricular failure. J Cardiovasc Pharmacol. 1989 Jul;14(1):103-8. PubMed PMID: 2475700. 6: Engel J, Bekel H, Heiliger D, Schaumlöffel E. [14C-labeling of alifedrine hydrochloride, a new positive inotropic compound]. Arch Pharm (Weinheim). 1985 May;318(5):465-7. German. PubMed PMID: 4026541. 7: Bickel E, Engel J, Klingler KH. [Syntheses of 14C-1-erythro-norephedrine and its N-substitution products 14C-oxyfedrine and 14C-D 13,625]. Arzneimittelforschung. 1983;33(9):1213-5. German. PubMed PMID: 6685500. 8: Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2. N Engl J Med. 1986 Feb 6;314(6):349-58. Review. PubMed PMID: 2418353.
|
|---|
| Molecular Formula |
C18H28CLNO2
|
|---|---|
| Molecular Weight |
325.877
|
| Exact Mass |
289.2
|
| Elemental Analysis |
C, 66.34; H, 8.66; Cl, 10.88; N, 4.30; O, 9.82
|
| CAS # |
72913-80-5
|
| Related CAS # |
72913-80-5 (HCl);78756-61-3;
|
| SMILES |
O=C(C1CCCCC1)CCN[C@@H](C)[C@H](O)C2=CC=CC=C2.[H]Cl
|
| InChi Key |
AKEXDXACYGXMJG-DJKAKHFESA-N
|
| InChi Code |
InChI=1S/C18H27NO2.ClH/c1-14(18(21)16-10-6-3-7-11-16)19-13-12-17(20)15-8-4-2-5-9-15;/h3,6-7,10-11,14-15,18-19,21H,2,4-5,8-9,12-13H2,1H3;1H/t14-,18-;/m0./s1
|
| Chemical Name |
1-cyclohexyl-3-(((1R,2S)-1-hydroxy-1-phenylpropan-2-yl)amino)propan-1-one hydrochloride
|
| Synonyms |
Alifedrine; Alifedrine HCl; D 13625; D-13625; D13625
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0686 mL | 15.3431 mL | 30.6861 mL | |
| 5 mM | 0.6137 mL | 3.0686 mL | 6.1372 mL | |
| 10 mM | 0.3069 mL | 1.5343 mL | 3.0686 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
